
Axsome Therapeutics (AXSM) Stock Forecast & Price Target
Axsome Therapeutics (AXSM) Analyst Ratings
Bulls say
Axsome Therapeutics Inc. reported third-quarter revenues of $136.1 million, surpassing analyst expectations and reflecting a robust year-over-year growth of 69% alongside a sequential increase of 14%. The company has enhanced payer coverage to 85%, which sets a positive foundation for future sales growth, particularly with ongoing clinical studies that address unmet needs in CNS disorders. With projections indicating faster revenue growth compared to operating costs, Axsome anticipates achieving cash flow positivity by 2026, bolstered by strong performance from its product pipeline.
Bears say
Axsome Therapeutics faces a challenging outlook largely due to a modest decrease in its full-year 2025 revenue forecast, which reflects ongoing risks such as lower-than-expected market access for its product AUVELITY and setbacks in clinical trials for key candidates like AXS-05. The company has encountered significant setbacks, including a failed Phase 3 trial for major depressive disorder and potential delays in securing regulatory approvals for its pipeline products, AXS-12 and AXS-14. Furthermore, heightened competition and lower market penetration could lead to reduced commercial success, alongside concerns of long-term dilution risk, impacting investor confidence.
This aggregate rating is based on analysts' research of Axsome Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Axsome Therapeutics (AXSM) Analyst Forecast & Price Prediction
Start investing in Axsome Therapeutics (AXSM)
Order type
Buy in
Order amount
Est. shares
0 shares